Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical challenges in breast care for patients with PTEN pathogenic variants: A case series and literature review
    Journal Article

    Williams, A. D.; LaRoy, J.; Le, T.; Mangino, D. A.; Robson, M. E.; Heerdt, A. S.; Moo, T. A.
    Surgical Oncology Insight (2024)

    Fulltext@MSK | Save
  • A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma
    Meeting Abstract

    Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mis-splicing derived neoantigens and cognate T cell receptors in splicing factor mutant myeloid neoplasms
    Meeting Abstract

    Kim, W. J.; Crosse, E. I.; De Neef, E.; Etxeberria, I.; Sabio, E.; Wang, E.; Bewersdorf, J. P.; Lu, S. X.; Belleville, A.; Fox, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Breast cancer susceptibility gene sequence variations and development of contralateral breast cancer
    Journal Article

    Reiner, A. S.; Watt, G. P.; Malone, K. E.; Lynch, C. F.; John, E. M.; Knight, J. A.; Woods, M.; Liang, X.; Tischkowitz, M.; Conti, D. V.; more...
    JAMA Network Open (2024)

    Fulltext@MSK | Save
  • Neoadjuvant immunotherapy in patients with early-stage, high-risk, ER+/HER2-breast cancer: Physician practices, therapy choice, and barriers among us oncologists
    Meeting Abstract

    Aggarwal, P.; Van Doren, B.; Jeune-Smith, Y.; Jennings-Zhang, L.; Bone, R. N.; Sadeghi, S.; Iyengar, N. M.; Feinberg, B.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
    Meeting Abstract

    Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+or HER2-low unresectable or metastatic (M) breast cancer (BC)
    Meeting Abstract

    George, M.; Frenel, J. S.; CorteĢs, J.; Schmidt, M.; Saenz, J. A. G.; Blau, S.; Abdulla, N. E.; Nishimura, M.; Sakai, H.; Babu, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC)
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Im, S. A.; Simon, S. P.; De Laurentiis, M.; Wang, S.; Martinez, N.; Borges, G. S.; Cescon, D.; Hattori, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Meeting Abstract

    Ueno, N. T.; Niikura, N.; Yamashita, T.; Jacot, W.; Cameron, D. A.; Tsurutani, J.; Sohn, J.; Tokunaga, E.; Losada, M. J. V.; Park, Y. H.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save